Daratumumab: Advancing Research in Multiple Myeloma and Beyond

Daratumumab is a monoclonal antibody that targets CD38, a protein highly expressed on the surface of multiple myeloma cells.

It binds to CD38, triggering immune-mediated destruction of cancer cells through mechanisms like complement-dependent cytotoxicity and antibody-dependent cellular cytotoxicity.

Daratumumab is primarily used in the treatment of multiple myeloma, both as a monotherapy and in combination with other therapies. Research is also exploring its potential in other hematologic cancers.

Daratumumab is a groundbreaking therapeutic monoclonal antibody that revolutionized the treatment landscape for multiple myeloma. By targeting CD38, a protein ubiquitously expressed on myeloma cells, it has become a cornerstone in immunotherapy for hematologic malignancies.

Daratumumab operates by binding to the CD38 protein on cancer cells. This binding activates immune responses that kill the cancer cells through various pathways:

• Complement-Dependent Cytotoxicity (CDC): Activates the complement system to destroy cells.
  
  
• Antibody-Dependent Cellular Cytotoxicity (ADCC): Engages immune cells to attack the cancer cells.
  
  
• Apoptosis: Induces programmed cell death directly in tumor cells.

Daratumumab has shown remarkable efficacy in treating multiple myeloma, improving survival rates and disease management outcomes. It is approved for use in:

• Newly diagnosed patients.
• Patients with relapsed or refractory disease.

Ongoing studies are investigating daratumumab's efficacy in other cancers, including non-Hodgkin lymphoma and chronic lymphocytic leukemia.

A biosimilar is a biologic medical product highly similar to an already approved reference product, with no clinically meaningful differences in safety, purity, or potency.